Literature DB >> 12358070

Prevalence of resistant Helicobacter pylori isolates in Bulgarian children.

Lyudmila Boyanova, Radka Koumanova1, Galina Gergova, Maria Popova1, Ivan Mitov, Youlia Kovacheva1, Sirigan Derejian1, Nikolai Katsarov1, Rossen Nikolov1, Zacharii Krastev1.   

Abstract

The aim of this study was to assess the primary and combined resistances of Helicobacter pylori isolates obtained from paediatric patients in 2000-2001 to seven antimicrobial agents. Resistance rates of pre-treatment isolates from 115 children were investigated by the limited agar dilution method alone and by the E-test. The cut-off concentrations for resistance were: metronidazole >8 mg/L, clarithromycin and azithromycin >1 mg/L, clindamycin >4 mg/L, amoxicillin >0.5 mg/L, tetracycline >4 mg/L and ciprofloxacin >1 mg/L. Primary resistance rates were: metronidazole 15.8%, clarithromycin 12.4%, azithromycin 14.6%, clindamycin 20.0%, amoxicillin 0%, metronidazole + clarithromycin 4.5%, ciprofloxacin 6.0%, metronidazole + clarithromycin + ciprofloxacin 1.2%, tetracycline 3.1% and metronidazole + ciprofloxacin 1.2%. There were no significant age (1-9 years versus 10-18 years) or gender differences. Prevalence of both macrolide-resistant and intermediately susceptible strains was 21.9% for azithromycin and 15.9% for clarithromycin. Of 18 metronidazole-resistant isolates, 77.8% exhibited a metronidazole MIC > or = 32 mg/L. H. pylori resistance rates to metronidazole, clarithromycin and both agents were relatively low in Bulgarian children. However, resistance was found to all drugs tested except for amoxicillin. The consumption of newer macrolides and tetracyclines could be related to the prevalence of resistance to the corresponding agents. There were no significant differences in primary resistance rates of H. pylori to antimicrobial agents between children and adults except for metronidazole. Multi-drug resistance to newer macrolides, metronidazole and ciprofloxacin in association with a slightly elevated amoxicillin MIC (0.38 mg/L) was detected in one strain.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12358070     DOI: 10.1099/0022-1317-51-9-786

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  6 in total

Review 1.  H pylori antibiotic resistance: prevalence, importance, and advances in testing.

Authors:  F Mégraud
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

2.  Antimicrobial susceptibility of Helicobacter pylori strains isolated from patients in Shiraz, Southern Iran.

Authors:  Shohreh Farshad; Abdolvahab Alborzi; Aziz Japoni; Reza Ranjbar; Kazem Hosseini Asl; Parisa Badiee; Maneli Amin Shahidi; Marziyeh Hosseini
Journal:  World J Gastroenterol       Date:  2010-12-07       Impact factor: 5.742

3.  Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea.

Authors:  Jung Mogg Kim; Joo Sung Kim; Hyun Chae Jung; Nayoung Kim; Young-Jeon Kim; In Sung Song
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

4.  Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005.

Authors:  Intetsu Kobayashi; Kazunari Murakami; Mototsugu Kato; Seiichi Kato; Takeshi Azuma; Shin'ichi Takahashi; Naomi Uemura; Tsutomu Katsuyama; Yoshihiro Fukuda; Ken Haruma; Masaru Nasu; Toshio Fujioka
Journal:  J Clin Microbiol       Date:  2007-10-17       Impact factor: 5.948

5.  Antibiotic susceptibility profile of Helicobacter pylori isolated from the dyspepsia patients in Tehran, Iran.

Authors:  Leila Shokrzadeh; Fereshteh Jafari; Hossein Dabiri; Kaveh Baghaei; Homayoun Zojaji; Amir H Alizadeh; Mohammad Mehdi Aslani; Mohammad R Zali
Journal:  Saudi J Gastroenterol       Date:  2011 Jul-Aug       Impact factor: 2.485

6.  Analysis of antimicrobial susceptibility and virulence factors in Helicobacter pylori clinical isolates.

Authors:  Anita Paula Ortiz Godoy; Marcelo Lima Ribeiro; Yune Helena Borges Benvengo; Lea Vitiello; Maira de Carvalho Bueno Miranda; Sergio Mendonça; José Pedrazzoli
Journal:  BMC Gastroenterol       Date:  2003-08-11       Impact factor: 3.067

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.